| Humana Medicare Advantage | Genetic Testing for Hematologic Malignancies and Suspected Myeloid Disorders - Medicare Advantage | 2026-04-01 |
| Humana Medicare Advantage | Genetic Testing for Hereditary Colorectal and Uterine Cancer - Medicare Advantage | 2026-04-01 |
| UHC Surest Medical and Drug | Papzimeos™ (Zopapogene Imadenovec-Drba) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| UHC UMR Medical and Drug | Papzimeos™ (Zopapogene Imadenovec-Drba) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| Oscar Insurance Guidelines | Benefit Preferred Physician-Administered Drug Exceptions Criteria | 2026-04-01 |
| Oscar Insurance Guidelines | Physician-Administered Drug Exceptions Criteria | 2026-04-01 |
| UHC UMR Medical and Drug | Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Surest Medical and Drug | Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Cardiovascular Disease Risk Tests – Commercial and Individual Exchange Medical Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Category III Codes – Commercial and Individual Exchange Medical Policy | 2026-04-01 |